Androgenic AlopeciaNCT07287579
Comparison Between Platelet Rich Plasma and Nanofat as an Adjuvant Therapy in HairTransplantation
A study testing hair transplantation in people with Androgenic Alopecia, run by Sohag University.
Trial summary
To compare the efficacy of platlet rich plasma and Nanofat injection as adjuvant therapies with FUE hair transplantation in improving graft survival rate, To measure hair density and thickness postoperatively using dermoscopy or trichoscopy. Read more about this study
- Who is it for?
- Ages 20 to 50 years, men only
- Conditions the study is for
- Androgenic Alopecia
- What is being tested?
- hair transplantation
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- No sites listed yet
- Study dates
- Jan 2026to Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 50 years
- Men only
- No healthy volunteers
- Adult
Who may be able to join
- 1. Male patients with stable androgenic alopecia more than 2 years. 2. Age 20-50 years 3. No recent medical hair loss treatments.
Who cannot join
- 1. Active scalp infections or scarring alopecia. 2. Systemic diseases affecting wound healing. 3. Platelet disorders or anticoagulant use. 4. Smoking or heavy alcohol intake
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Comparison Between Platelet Rich Plasma and Nanofat as an Adjuvant Therapy in Hair Transplantation in Male Androgenic Alopecia
- To compare the efficacy of platlet rich plasma and Nanofat injection as adjuvant therapies with FUE hair transplantation in improving graft survival rate,
- To measure hair density and thickness postoperatively using dermoscopy or trichoscopy.
- To evaluate patient satisfaction and photographic assessment by blinded evaluators.
- To assess any adverse effects or complications related to each modality
Read the detailed description
- Ideal candidates for hair transplantation typically present with a clear, stable pattern of hair loss, characterized by at least 50% thinning or balding in 1 or more areas. The scalp must be healthy, with donor hair of good quality and quantity. Patients must have realistic expectations and be free of medical conditions that compromise surgical outcomes. The safe donor zone is located in the mid-occipital region between the upper and lower occipital protuberances, typically containing 65 to 85 follicular units/cm²
- Intra-operative injection of PRP is beneficial in giving faster density, reducing the catagen loss of transplanted hair, early recovery of the skin, the faster appearance of new anagen hair in FUE hair transplantation.
- This study compares the effects of PRP and Nano fat as adjuvants in Androgenic alopecia patients undergoing FUE hair transplantation.
- Nanofat contain stem cells supposed to improve the results of FUE hair transplantation , but the question that we hope to answer at the end of our study which one we recommend as an adjuvant therapy PRP or Nano fat?
- Conditions
- Androgenic Alopecia
- Being tested
- hair transplantation
- Keywords
- hair transplantation
- Medical subject headings
- Alopecia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
hair transplantationProcedure or surgery
Also called hair transplantation with platelet rich plasma, hair transplantation with nanofat injection
we compare the effect of nanofat injection and platelet rich plasma in hair transplantation in male androgenic alopecia
| Study group | Role | What they receive |
|---|---|---|
| group a | Experimental | hair transplantation done alone without platelet rich plasma or nanofat injection Receives: Procedure: hair transplantation |
| group b | Experimental | we do injection of platelet rich plasma with hair transplantation Receives: Procedure: hair transplantation |
| group c | Experimental | we do injection of nanofat with hair transplantation Receives: Procedure: hair transplantation |
What is being measured
The primary outcome is the main question the study is designed to answer.
• To measure hair density using dermoscopy.
To measure how many hair follicles in each cubic centimetre
Measured: • All patients will be followed up about 6-12 months postoperative.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Dec 2025
- Study startJan 2026 (estimated)
- Primary completionJun 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Androgenic AlopeciaStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Shenoda Gamel Fayez, Sohag University
- Investigators
- samia saied, MD, Study chair, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07287579
- Sponsor's protocol ID
- Soh-Med--25-11-1MD
- Status last verified
- Nov 2025
- First submitted
- 22 Nov 2025
- Last updated
- 17 Dec 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Evin N, Guray Evin S. Camouflage of Postburn Scarring Alopecia Using Nanofat Grafting and Follicular Unit Hair Transplantation. Plast Reconstr Surg. 2024 Jul 1;154(1):207-215. doi: 10.1097/PRS.0000000000010759. Epub 2023 May 26.
PubMed 37253046
Study at a glance
From the registry record, last updated by the sponsor on 17 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison Between Platelet Rich Plasma and Nanofat as an Adjuvant Therapy in Hair Transplantation in Male Androgenic Alopecia
- ClinicalTrials.gov ID
- NCT07287579
- Acronym / sponsor ID
- Soh-Med--25-11-1MD
- Conditions
- Androgenic Alopecia
- Keywords
- hair transplantation
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- Jan 2026 (estimated)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 17 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- To compare the efficacy of platlet rich plasma and Nanofat injection as adjuvant therapies with FUE hair transplantation in improving graft survival rate,
- To measure hair density and thickness postoperatively using dermoscopy or trichoscopy.
- To evaluate patient satisfaction and photographic assessment by blinded evaluators.
- To assess any adverse effects or complications related to each modality
Detailed description
- Ideal candidates for hair transplantation typically present with a clear, stable pattern of hair loss, characterized by at least 50% thinning or balding in 1 or more areas. The scalp must be healthy, with donor hair of good quality and quantity. Patients must have realistic expectations and be free of medical conditions that compromise surgical outcomes. The safe donor zone is located in the mid-occipital region between the upper and lower occipital protuberances, typically containing 65 to 85 follicular units/cm²
- Intra-operative injection of PRP is beneficial in giving faster density, reducing the catagen loss of transplanted hair, early recovery of the skin, the faster appearance of new anagen hair in FUE hair transplantation.
- This study compares the effects of PRP and Nano fat as adjuvants in Androgenic alopecia patients undergoing FUE hair transplantation.
- Nanofat contain stem cells supposed to improve the results of FUE hair transplantation , but the question that we hope to answer at the end of our study which one we recommend as an adjuvant therapy PRP or Nano fat?
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| group a | Experimental | Procedure: hair transplantationhair transplantation done alone without platelet rich plasma or nanofat injection |
| group b | Experimental | Procedure: hair transplantationwe do injection of platelet rich plasma with hair transplantation |
| group c | Experimental | Procedure: hair transplantationwe do injection of nanofat with hair transplantation |
Who may qualify
- Ages
- 20 to 50 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- 1. Male patients with stable androgenic alopecia more than 2 years. 2. Age 20-50 years 3. No recent medical hair loss treatments.
Key exclusion criteria (1 listed)
- 1. Active scalp infections or scarring alopecia. 2. Systemic diseases affecting wound healing. 3. Platelet disorders or anticoagulant use. 4. Smoking or heavy alcohol intake
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| hair transplantationAlso: hair transplantation with platelet rich plasma, hair transplantation with nanofat injectionwe compare the effect of nanofat injection and platelet rich plasma in hair transplantation in male androgenic alopecia | Procedure or surgery | group a, group b, group c |
Primary outcome
• To measure hair density using dermoscopy.
Time frame: • All patients will be followed up about 6-12 months postoperative.
To measure how many hair follicles in each cubic centimetre
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Dec 2025.
- Background: PubMed 37253046Evin N, Guray Evin S. Camouflage of Postburn Scarring Alopecia Using Nanofat Grafting and Follicular Unit Hair Transplantation. Plast Reconstr Surg. 2024 Jul 1;154(1):207-215. doi: 10.1097/PRS.0000000000010759. Epub 2023 May 26.
- Outcome of Intra-operative Injected Platelet-rich Plasma Therapy During Follicular Unit Extraction Hair Transplant: A Prospective Randomised Study in Forty PatientsLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Androgenic Alopecia
Not yet recruitingPhase 2
Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia
Androgenetic Alopecia
Not yet recruitingPhase 3
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.
Androgenetic Alopecia, Androgenetic Alopecia (AGA)
Not yet recruiting
Study to Evaluate Xtressé Gummy Supplement in Women With Thinning Hair
Androgenetic Alopecia
Not yet recruitingEarly Phase 1
Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia
Androgenic Alopecia
Not yet recruitingPhase 3
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)
Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
samia saied, MD study chair
Sohag University
Questions about this trial
What is this clinical trial studying?
A study testing hair transplantation in people with Androgenic Alopecia, run by Sohag University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 17 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact shenouda Faiez, AL (0201285122844, shenoda011111@med.sohag.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
• To measure hair density using dermoscopy. (time frame: • All patients will be followed up about 6-12 months postoperative.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07287579, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Dec 2025.